Doxycycline

Generic Name: Doxycycline

Brand Names: Acticlate, Adoxa, Apprilon, Atridox, Doryx, Doxy, Doxycin, Lymepak, Mondoxyne, Monodox, Morgidox, Okebo, Oracea, Periostat, Targadox, Vibramycin

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄N_₂O_₈

CAS Number: 564-25-0

Unique Ingredient Identifier: 334895S862

Background: Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is...

Indication: Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including:

It is also used to treat infections caused by the following gram-negative microorganisms:

Associated Conditions: Acinetobacter Infections, Anthrax, Bacterial Infection caused by Enterobacter aerogenes, Bartonellosis, Brucellosis, Campylobacter Infection, Chancroid, Chlamydia Trachomatis Infection, Early Lyme Disease, Granuloma Inguinale, Infection Due to Escherichia Coli, Inhalational Anthrax, Klebsiella Infections, Lymphogranuloma Venereum, Malaria caused by Plasmodium falciparum, Nongonococcal urethritis, Plague caused by Yersinia pestis, Psittacosis, Rectal infection caused by Chlamydia Trachomatis, Relapsing fever caused by Borrelia recurrentis, Respiratory Tract Infection Bacterial, Rickettsial infectious disorders, Severe Acne, Sexually Transmitted Infections (STIs), Shigella Infection, Trachoma inclusion conjunctivitis, Tularemia, Vibrio Cholerae Infection, Acute Intestinal amebiasis, Susceptible Bacterial Infections, Uncomplicated endocervical infection, Uncomplicated urethral infection

Associated Therapies: -

Clinical Trials

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo

Phase 4

Completed

Conditions: Rosacea

Interventions: Drug: Placebo
Drug: Doxycycline
Drug: Metronidazole

First Posted Date: 2011-08-31

Last Posted Date: 2022-08-01

Lead Sponsor: Galderma R&D

Target Recruit Count: 235

Registration Number: NCT01426269

Locations: 🇺🇸
ATS Clinical Research, Santa Monica, California, United States
🇺🇸
Melissa L. F. Knuckles M.D., P.S.C., Richmond, Kentucky, United States
🇺🇸
Dadeland Dermatology, Coral Gables, Florida, United States

and more 7 locations

Effectiveness of Doxycycline for Treating Pleural Effusions Related to Cancer in an Outpatient Population

Phase 2

Conditions: Malignant Pleural Effusion

Interventions: Other: normal saline
Drug: Doxycycline

First Posted Date: 2011-08-08

Last Posted Date: 2020-09-25

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 40

Registration Number: NCT01411202

Locations: 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦
Ottawa Hospital, Ottawa, Ontario, Canada

Development of an Optimal Antibiotic Regime for Long-term Therapy in Stable Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Conditions: Chronic Obstructive Pulmonary Disease (COPD).

Interventions: Drug: Placebo
Drug: Moxifloxacin
Drug: Azithromycin
Drug: Doxycycline

First Posted Date: 2011-07-20

Last Posted Date: 2012-06-01

Lead Sponsor: University College, London

Target Recruit Count: 200

Registration Number: NCT01398072

Locations: 🇬🇧
Academic Unit of Respiratory Medicine, Royal Free Hospital, London, United Kingdom

Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans

Phase 4

Completed

Conditions: Type 2 Diabetes
Obesity

Interventions: Other: Placebo
Drug: Doxycycline

First Posted Date: 2011-06-17

Last Posted Date: 2020-01-13

Lead Sponsor: University of California, San Diego

Target Recruit Count: 39

Registration Number: NCT01375491

Locations: 🇺🇸
University of California San Diego Clinical trials Research Institute, La Jolla, California, United States

Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice

Phase 4

Completed

Conditions: Erythema Migrans
Lyme Disease
Erythema Chronicum Migrans
Early Lyme Disease
Borreliosis

Interventions: Drug: Phenoxymethylpenicillin
Drug: Amoxicillin
Drug: Doxycycline

First Posted Date: 2011-06-07

Last Posted Date: 2014-12-12

Lead Sponsor: Morten Lindbaek

Target Recruit Count: 225

Registration Number: NCT01368341

Locations: 🇳🇴
Antibiotic Centre for Primary Care, University of Oslo, Oslo, Norway

Doxycycline Effects on Inflammation in Cystic Fibrosis

Phase 4

Completed

Conditions: Cystic Fibrosis

Interventions: Other: No doxycycline
Drug: Doxycycline

First Posted Date: 2011-03-25

Last Posted Date: 2017-03-30

Lead Sponsor: University of Southern California

Target Recruit Count: 21

Registration Number: NCT01323101

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment

Phase 4

Completed

Conditions: Fatigue Syndrome, Chronic
Q Fever
Coxiella Infection

Interventions: Behavioral: Cognitive behavioral therapy
Drug: Placebo
Drug: Doxycycline

First Posted Date: 2011-03-18

Last Posted Date: 2021-06-23

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 156

Registration Number: NCT01318356

Locations: 🇳🇱
Radboud university medical center, Nijmegen, Gelderland, Netherlands

Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer

Not Applicable

Terminated

Conditions: Colorectal Cancer Metastatic
Skin Toxicity

Interventions: Drug: Doxycycline
Drug: Cetuximab

First Posted Date: 2011-03-17

Last Posted Date: 2020-03-25

Lead Sponsor: Institut Cancerologie de l'Ouest

Target Recruit Count: 25

Registration Number: NCT01317433

Locations: 🇫🇷
ICO Paul Papin, Angers, France
🇫🇷
CHU Jean Minjoz, Besançon, France
🇫🇷
Centre Hospitalier Départemental Les Oudairies, La Roche Sur Yon, France

and more 2 locations

Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo

Phase 4

Completed

Conditions: Rosacea

Interventions: Other: Placebo
Drug: Doxycycline

First Posted Date: 2011-03-04

Last Posted Date: 2022-08-01

Lead Sponsor: Galderma R&D

Target Recruit Count: 170

Registration Number: NCT01308619

Locations: 🇺🇸
Michigan Center for Research Corp, Clinton Township, Michigan, United States
🇺🇸
Burke Pharmaceutical Research, Hot Springs, Arkansas, United States
🇺🇸
Oregon Medical Research Center, PC, Portland, Oregon, United States

and more 7 locations

A Novel Combination Oral Agent to Treat Acne Vulgaris

Phase 1

Conditions: ACNE VULGARIS

Interventions: Drug: Doxycycline and S-equol
Drug: Doxycycline

First Posted Date: 2011-02-23

Last Posted Date: 2011-02-23

Lead Sponsor: Nexgen Dermatologics, Inc.

Target Recruit Count: 60

Registration Number: NCT01301586

Locations: 🇺🇸
Berlin Center, Boynton Beach, Florida, United States
🇺🇸
Palos Verdes Dermatology Associates, Rolling Hills Estates, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy